Can you go higher than 2.4mg on Wegovy? What the evidence shows

What the approval of 7.2mg actually means — and where the evidence comes from

For most of Wegovy's licensed history, 2.4mg was the ceiling. That changed on 14 January 2026 when the MHRA approved 7.2mg semaglutide as a new maximum maintenance dose, initially supplied as three 2.4mg pens administered weekly. On 14 April 2026, a dedicated single-dose 7.2mg pen followed, with an auto-dosing mechanism, a built-in covered needle, and a lock that activates after use. The MHRA's announcement confirms the approval details for anyone who wants to read the regulator's own words.

The trial data behind this approval is striking. Across 72 weeks, participants on 7.2mg semaglutide achieved around 20.7% average weight loss. That figure closes a meaningful portion of the gap between 2.4mg Wegovy (which produced roughly 15% average reduction in the STEP 1 trial) and tirzepatide at its highest dose. For people who tolerated 2.4mg well but wanted more, the clinical case for a higher ceiling became hard to ignore.

If you have been wondering whether there is a higher dose of Wegovy than 2.4mg, you can read our overview of the Wegovy new higher dose to understand what the MHRA approval of 7.2mg makes possible. The 7.2mg dose is licensed specifically for adults with a BMI of 30 or above. It is not approved for the lower BMI threshold used in some other Wegovy indications, and it sits outside the cardiovascular risk-reduction licence. A prescriber will assess which indication and dose applies to your situation.

How titration to a higher dose actually works in practice

People sometimes assume that moving to a Wegovy dose higher than 2.4mg means simply switching pens. In practice, semaglutide titration does not work that way. Treatment still begins at 0.25mg, progressing roughly every four weeks through 0.5mg, 1.0mg, 1.7mg and 2.4mg before a prescriber might consider the 7.2mg maintenance dose. Each step exists to let your body adjust to the medicine's GI effects — pushing through the schedule faster tends to mean more nausea, not better results.

Patients already established on the 2.4mg weekly injection who move toward 7.2mg do so under clinical guidance, not by self-escalating. Your prescriber will weigh your response so far, your tolerance of previous doses, and your broader health picture. For context on the full dose ladder, the Wegovy dose schedule page walks through each rung and what to expect.

The question of whether starting at a higher dose is ever appropriate is one our clinical team addresses regularly. The short answer is no, the titration schedule exists for good reasons, and skipping it is not supported by the evidence or the licence.

Who the 7.2mg dose is licensed for, and what changes for private patients

The 7.2mg maintenance dose is for adults with a BMI of 30 or above, the same BMI entry point as the standard Wegovy weight-management licence. If your BMI sits between 27 and 29.9 with a weight-related condition, the existing 2.4mg licence already covers you, but the 7.2mg approval does not extend there. This distinction matters when thinking about whether a higher dose could even be prescribed for you.

For NHS patients, access to semaglutide at any dose is subject to the criteria set out under NICE technology appraisal TA875, which requires treatment within a specialist weight management service. The NICE appraisal of semaglutide (TA875) also sets a maximum treatment duration of two years. Those constraints apply regardless of which dose reaches the market. Waiting lists for specialist services remain long in most areas.

Private patients working with a regulated prescriber face a different picture. If you are thinking about where to look at how Wegovy pricing breaks down privately, it is worth understanding that dose affects cost, and that any legitimate private prescription follows the same clinical process (assessment, approval, titration) as an NHS one. There are no shortcuts through a regulated service, and there should not be. For a broader look at what the Wegovy higher dose involves and who it suits, that page covers the transition question in more detail.

Side effects and monitoring at higher doses

The side-effect profile at 7.2mg is broadly consistent with what is seen throughout semaglutide treatment, with gastrointestinal effects (nausea, loose stools, slowed digestion, occasionally vomiting) most likely to emerge at the point of a dose increase. They typically settle within a week or two as your body adjusts, though everyone's experience differs.

One safety point worth knowing: in January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious side effect across GLP-1 medicines. Severe, persistent stomach pain that radiates toward the back, with or without vomiting, warrants urgent medical attention. Report any unexpected side effects through the MHRA Yellow Card scheme, this applies at every dose level, and particularly when starting or increasing.

Pregnancy, breastfeeding, and the period before trying to conceive are all circumstances where semaglutide is not recommended. Under-18s are outside the licensed indication. These exclusions apply at 7.2mg just as they do at 2.4mg. If your circumstances change during treatment, discuss with your prescriber promptly, that is exactly the kind of question a clinical team is there for, and our FAQs page covers some of the most common ones.